Search Results - diabetes

43 Results Sort By:
Small Molecule Humanin Mimetics and Enhancers That Normalize Neuronal p-AKT as Novel Therapeutics for Alzheimer's Disease (UCLA Case No. 2023-230)
UCLA researchers in the Department of Neurology have discovered novel small molecule humanin mimetics for the treatment of Alzheimer's disease and other chronic conditions with dysregulated p-Akt. BACKGROUND: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60-70% of all cases. Nearly 7 million Americans are living...
Published: 7/22/2024   |   Inventor(s): Varghese John
Keywords(s): Alzheimers disease, Cardiovascular, Cardiovascular Disease, Dementia, diabetes, mimetics, pAKT signaling, small molecules
Category(s): Therapeutics > CNS and Neurology, Therapeutics > Cardiovascular
Localized In Vivo Electro Gene Therapy for Type 1 Diabetes
­Advantages: Novel gene therapy for Type 1 Diabetes (T1D) focused on reprogramming skeletal muscle cells to modulate glucose levels in vivo. Nano plasmid DNA of insulin and glucokinase decreased glucose levels in vitro and in vivo and enhanced insulin expression and secretion. Groundbreaking treatment for long-lasting blood glucose control...
Published: 7/2/2024   |   Inventor(s): Anna Bulysheva
Keywords(s): Diabetes, Medical Therapeutics Gene Therapy
Category(s): Technology Classifications > Medical > Biomedical Engineering, Technology Classifications > Medical > Biotechnology
Methylene Blue and Methylene Violet Analogs as Mitochondrial Therapeutic Agents
Mitochondrial dysfunction has been implicated in a number of diseases, including Alzheimer’s disease (AD), movement disorders, diseases of the cardiovascular system, cancer, diabetes, blindness and deafness. Mitochondrial defects are damaging, particularly to tissues with high energy demands such as neural and muscle tissues. Membrane-penetrating...
Published: 1/25/2024   |   Inventor(s): Sidney Hecht, Omar Khdour, Sandipan Roy Chowdhury, Nishant Visavadiya
Keywords(s): Alzheimer's Disease, Diabetes, Genetic Disorders, Metabolic Disorders, Mitochondrial medicine
Category(s): Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals
Methylene Blue and Methylene Violet Analogs as Mitochondrial Therapeutic Agents
Mitochondrial dysfunction has been implicated in a number of diseases, including Alzheimer’s disease (AD), movement disorders, diseases of the cardiovascular system, cancer, diabetes, blindness and deafness. Mitochondrial defects are damaging, particularly to tissues with high energy demands such as neural and muscle tissues. Membrane-penetrating...
Published: 1/25/2024   |   Inventor(s): Sidney Hecht, Omar Khdour, Sandipan Roy Chowdhury, Indrajit Bandyopadhyay
Keywords(s): Alzheimer's Disease, Diabetes, Genetic Disorders, Metabolic Disorders, Mitochondrial medicine, Neurodegenerative Disorders, Parkinson's Disease, Pharmaceutical
Category(s): Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals
Compounds that Interfere with the Androgen Receptor Complex
Abstract: Investigators at the National Institutes of Health (NIH) have discovered compounds that have potential as novel anti-androgen therapeutics. The immunophilin protein FKBP52 is part of a protein complex that helps fold the androgen receptor (AR) protein, a target for treating prostate cancer, and enhances its activity. Disruption of the FKPB52-AR...
Published: 4/8/2024   |   Inventor(s): Leonard Neckers, Jane Trepel Neckers, Yeong Kim, Aki Iwai, Yangmin Ning, Marc Cox, Johanny Meneses De Leon, Heather Balsiger, Robert Fletterick
Keywords(s): androgen receptor protein, DIABETES, PROSTATE CANCER
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology
Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis
Abstract: Over 32 million Americans are living with Diabetes and newly diagnosed cases of type 1 and type 2 diabetes is increasing. A defining feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide (IAPP) fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Mounting...
Published: 4/8/2024   |   Inventor(s): Qing Rong Liu, Min Zhu, Pingbo Zhang, Josephine Egan, Luigi Ferrucci
Keywords(s): Alzheimer’s Disease, Amyloidosis, C-peptide, DIABETES, Egan, insulin, Islet Amyloid Polypeptide, Liu, National Institute on Aging, NIA
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Endocrinology
IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment.  The...
Published: 4/8/2024   |   Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi
Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Renal Selective Unsaturated Englerin Analogues
Abstract: Englerin A, a natural product, has shown growth-inhibiting activity against renal cancer cell lines. The compound is an agonist of protein kinase C (PCK) theta, which results in cell cytotoxicity, insulin inhibition, and selective activation of viral replication in T cells.  Englerin A derivatives are promising treatment strategies for any...
Published: 4/8/2024   |   Inventor(s): John Beutler, Tanya Ransom, Antonio Echavarren, Frederic Ratel
Keywords(s): Beutler, DIABETES, HIV, renal cancer, small molecule
Category(s): TherapeuticArea > Endocrinology, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease
Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation
Abstract: Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer’s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-β is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to β-cell dysfunction....
Published: 5/23/2024   |   Inventor(s): Qing Rong Liu, Min Zhu, Josephine Egan
Keywords(s): Ad, Age-Associated Disease, Alzheimer’s Disease, Amyloidosis, Amyloids, Biomarkers, DIABETES, IAPP, Islet Amyloid Polypeptide Isoforms, Liu, National Institute on Aging, NIA, PEPTIDYL
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Type 1 Diabetes Biomarkers
Type 1 Diabetes (T1D) is one of the most common juvenile autoimmune diseases and is characterized by progressive destruction of pancreatic ß-cells. By the time of T1D diagnosis, around 70-90% of pancreatic ß-cells are already dead. T1D patients face many potential health complications and co-morbidities which lead to both personal and societal...
Published: 2/23/2023   |   Inventor(s): Joshua LaBaer, Ji Qiu, Xiaofang Bian, Desmond Schatz, Clive Wasserfall, Mark Atkinson
Keywords(s): Autoantibody, Bioanalysis, biomarker, Detection, Diabetes, Diagnostics, Early Detection, ELISA, Screening
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Proteomic Assays/Reagents/Tools
1 2 3 4 5